Chai Discovery Secures $400M to Transform AI Drug Discovery
SAN FRANCISCO, July 17, 2026 Chai Discovery has announced the successful completion of a $400 million Series C financing...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN FRANCISCO, July 17, 2026 Chai Discovery has announced the successful completion of a $400 million Series C financing...
NEW YORK and ATHENS, Greece, June 13, 2026 Kos Biotechnology Partners has announced the successful third closing of its...
BOSTON and YOKNEAM, Israel, May 14, 2026 Butterfly Medical announced the successful completion of an upsized $21 million Series...
CAMBRIDGE, Massachusetts, April 2026 Iterative Health announced the successful close of a $77 million Series C funding round, reinforcing...
SAN DIEGO, CA — November 20, 2025 — Aspen Neuroscience, a leading developer of personalized autologous cell therapies for...
Munich, Germany, October 30, 2025 — Tubulis GmbH announced the successful second and final closing of its Series C...
